To include your compound in the COVID-19 Resource Center, submit it here.

Bydureon exenatide once weekly regulatory update

Amylin submitted a reply to a complete response letter from FDA for Type II diabetes candidate once-weekly Bydureon exenatide.

Read the full 196 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE